Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| LYNK Pharmaceuticals | Hangzhou | Series C | $16.7M | 2023-09-21 |
| Bivision | Shanghai | Series B | $58.8M | 2026-05-18 |
| Atom Bioscience & Pharmaceutical | Suzhou | Series D | $82.1M | 2023-10-16 |
| Minova Pharma | Nanjing | Series B | $14.0M | 2025-08-25 |
| Elevoc | Shenzhen | Series B | $15.0M | 2021-04-26 |
| Levinthal | Hangzhou | Seed | $1K | 2025-12-09 |
| Zhiyan Technology | Hangzhou | Series B | $15.7M | 2021-12-09 |
| Realibox | Guangzhou | Series A | $14.0M | 2022-09-26 |
8 rows of the CSV in 5 of its 18 columns.
- The 33 Kaitai Capital portfolio companies have raised $211.5M in total.
- 3 of them closed their most recent round in the last 12 months, $58.8M combined.
- The largest of those rounds is Bivision's $58.8M Series B, dated May 2026.
- Fortune Venture Capital is an investor in 2 of them, more than any other fund.
- Software is the most common sector, with 21 companies (64%).
- 15% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (47% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
8 of 33| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| Levinthal | Levinthal uses artificial intelligence for protein design and co-evolution in food safety and medical care. | Artificial intelligence | Hangzhou, China | Seed | $1K | 2025-12-09 | $1.6M | ZhenFund, Kaitai Capital, Pan-Lin Capital +1 | 1 to 10 | 2021 |
| Atom Bioscience & Pharmaceutical | Atom Bioscience is a clinical-stage biotechnology company. | Biotech | Suzhou, China | Series D | $82.1M | 2023-10-16 | Fortune Venture Capital, Oriza Holdings, Kaitai Capital +1 | 11 to 50 | 2012 | |
| LYNK Pharmaceuticals | LYNK Pharmaceuticals is a biotech company that discovers and develops new medicines. | Biotech | Hangzhou, China | Series C | $16.7M | 2023-09-21 | Legend Capital, Kaitai Capital, New Alliance Capital +2 | 11 to 50 | 2018 | |
| Realibox | Realibox delivers digital design and cloud platform solutions for enterprises. | Hardware | Guangzhou, China | Series A | $14.0M | 2022-09-26 | Hillhouse Investment, Kaitai Capital, Chengwei Capital | 11 to 50 | 2018 | |
| Imperial Vision Technology | Imperial Vision Technology is an AI and robotics company. | Artificial intelligence | Foochow, China | Series A | $2.9M | 2018-09-21 | Kaitai Capital | 11 to 50 | 2016 | |
| Crabyter | Crabyter develops a platform for managing clinical scientific research data. | Biotech | Putuo, China | Series B | $2.9M | 2016-12-07 | $6.5M | PreAngel, Kaitai Capital, Prox Ventures +1 | 101 to 250 | 2013 |
| QY NODE | QY NODE is an artificial intelligence company working on health applications of genetic data. | Artificial intelligence | Shunyi, China | Angel | $808K | 2015-05-01 | $808K | Kaitai Capital | 11 to 50 | 2014 |
Table 1. Kaitai Capital portfolio companies: the 8 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 33.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bivision | Bivision researches and develops targeted radiopharmaceuticals for therapy. | Biotech | Shanghai, China | Series B | $58.8M | 2026-05-18 | $100.9M | Gaorong Capital, Kaitai Capital, Lichen Capital | 11 to 50 | 2021 |
| 2 | Levinthal | Levinthal uses artificial intelligence for protein design and co-evolution in food safety and medical care. | Artificial intelligence | Hangzhou, China | Seed | $1K | 2025-12-09 | $1.6M | ZhenFund, Kaitai Capital, Pan-Lin Capital +1 | 1 to 10 | 2021 |
Table 2. Kaitai Capital portfolio companies: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 2 | 6% | ||
| 2 | GSR United Capital | Venture capital firm | Beijing, China | 2 | 6% | ||
| 3 | Hillhouse Investment | Angel group | Singapore | 2 | 6% | ||
| 4 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 2 | 6% | ||
| 5 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 1 | 3% | ||
| 6 | New Alliance Capital | Private equity firm | Shanghai, China | 1 | 3% | ||
| 7 | Legend Capital | Venture capital firm | Beijing, China | 1 | 3% | ||
| 8 | Decheng Capital | Venture capital firm | Menlo Park, United States | 1 | 3% | ||
| 9 | Gaorong Capital | Venture capital firm | Wangjing, China | 1 | 3% | 1 | Bivision |
| 10 | Lichen Capital | Private equity firm | 1 | 3% | 1 | Bivision | |
| 11 | BlueRun Ventures | Venture capital firm | San Mateo, United States | 1 | 3% | 1 | Xihu Xinchen |
| 12 | Baidu Ventures | Venture capital firm | Beijing, China | 1 | 3% | 1 | Xihu Xinchen |
| 13 | West Lake Science and Technology Direct Investment Fund | Venture capital firm | Hangzhou, China | 1 | 3% | 1 | Xihu Xinchen |
| 14 | EFung Capital | Private equity firm | Shenzhen, China | 1 | 3% | ||
| 15 | Oriza Holdings | Venture capital firm | Suzhou, China | 1 | 3% |
Table 3. Kaitai Capital portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Software | 21 | 64% | $26.3M |
| Artificial intelligence | 13 | 39% | $26.3M |
| Biotech | 10 | 30% | $156.8M |
| Hardware | 9 | 27% | |
| Health care | 8 | 24% | $156.0M |
| Commerce | 2 | 6% | |
| Fintech | 2 | 6% | $12.1M |
| Cybersecurity | 1 | 3% |
Table 4. Kaitai Capital portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Kaitai Capital portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Kaitai Capital portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| August 2026 | 1 | 33% | |
| May 2026 | 1 | 33% | $58.8M |
| December 2025 | 1 | 33% | $1K |
Table 7. Kaitai Capital portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 2 | 6% | $58.8M |
| 2025 | 2 | 6% | $14.0M |
| 2024 | 2 | 6% | $1.4M |
| 2023 | 6 | 18% | $127.3M |
| 2022 | 7 | 21% | $44.9M |
| 2021 | 4 | 12% | $46.1M |
Table 8. Kaitai Capital portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2020 to 2022 | 5 | 15% |
| 2015 to 2019 | 18 | 55% |
| 2010 to 2014 | 9 | 27% |
| Before 2010 | 1 | 3% |
Table 9. Kaitai Capital portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 2 | 6% |
| 11 to 50 | 15 | 47% |
| 51 to 100 | 11 | 34% |
| 101 to 250 | 2 | 6% |
| 251 to 500 | 2 | 6% |
Table 10. Kaitai Capital portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Kaitai Capital is recorded as one of its investors. On 16 November 2026 that is 33 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 8 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 33 rows: 9 have no round amount, 0 no city and 13 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Kaitai Capital portfolio companies are on the list?
- 33, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 33 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.